The increasingprevalence of chronic and mental disorder is a key factor expected to enablegrowth in the globalschizophrenia drugs market, says FortuneBusiness Insights in a report, titled “SchizophreniaDrugs Market Size, Share & Industry Analysis, By Therapeutic Class (SecondGeneration, Third Generation, Others), By Treatment (Oral, Injectable), ByDistribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,and Others) and Regional Forecast, 2019-2026.” The global schizophreniadrugs market was valued at USD 6.75 Billion in 2018 and is projected to reachUSD 9.48 Billion by 2026, exhibiting a CAGR of 4.3% during the forecast period.
An Overview of the Impact of COVID-19 on this Market:
Theemergence of COVID-19 has brought the world to a standstill. We understand thatthis health crisis has brought an unprecedented impact on businesses acrossindustries. However, this too shall pass. Rising support from governments andseveral companies can help in the fight against this highly contagious disease.There are some industries that are struggling and some are thriving. Overall,almost every sector is anticipated to be impacted by the pandemic.
Weare taking continuous efforts to help your business sustain and grow duringCOVID-19 pandemics. Based on our experience and expertise, we will offer you animpact analysis of corona virus outbreak across industries to help you preparefor the future.
Click here to get theshort-term and long-term impact of COVID-19 on this [Market].
For More Information : https://www.fortunebusinessinsights.com/industry-reports/schizophrenia-drugs-market-101531
Rising Awareness About MentalDisorders Will Boost Growth
According toFortune Business Insights, the increasing cases of mental disorders such asschizophrenia will uplift the global schizophrenia drugs market shares. Thesurge in medical interventions for the treatment of major mental disorders willenable growth inthe global schizophrenia drugs market during the forecastperiod. Furthermore, the rising emphasis on mental illness and mental health inemerging nations will boost the global schizophrenia drugs market revenueduring the forecast period. Moreover, the increasing efficacy and safetyfeatures of treatment for schizophrenia will fuel demand among patientswhich,willin turn,accelerate the growth of the global schizophrenia drugs.
Launch Of REXULTITablets Will Propel Growth
OtsukaPharmaceutical Co., Ltd., a pharmaceutical company headquartered in Tokyolaunched REXULTI Tablets (chemical name is brexpiprazole) in 1 mg and 2 mgtablets for the treatment of schizophrenia in patients. Based on the efficacyof REXULTI in the treatment of schizophrenia, it is included in the JapaneseNational Health Insurance Drug Price List. The launch of REXULTI® Tabletswill favor growth to the global schizophrenia drugs market owing to thepresence of a novel compound in the tablets. REXULTI Tablets will bemarketed to healthcare institutions across Japan to treat patients with mentaldisorders.
Furthermore, according to the report published by FortuneBusiness Insights on the basis of treatment outlook the global schizophreniadrugs market is segmented into oral and injectable. Injectedbale basedtreatment is predicted to generate maximum revenue owing to the prevention ofrelapses and also the irreparable cognitive and neurological damages to thepatients.
MoreTrending Topics From Fortune Business Insights@
Coronary Guidewires Market , Share, Growth, Sales and Drivers AnalysisResearch Report 2026
